Does community size or commute time affect severity of illness at diagnosis or quality of care in a centralized care model of pulmonary hypertension?


      • In pulmonary hypertension, care is centralized in “Centers of Excellence”.
      • It is unclear how this effects patients who live in remote or rural places.
      • We found no association with severity of illness at diagnosis on catheterization.
      • We found no change in type of care, follow up tests or low risk status.
      • Patients who live in rural or remote areas do well with centralized care.


      Background: Centralized care models are often used for rare diseases like pulmonary hypertension (PH). It is unknown how living in a rural or remote area influences outcomes.
      Methods: We identified all patients from our PH database who carried a diagnosis of WHO Group 1 or WHO Group 4 PH. Using Canadian postal code data, patients were classified as living in a rural area; or a small, medium or large community size. The commute time from patient residence to our clinic was determined using mapping software. We compared baseline catheterization data according to community size and commute time. At follow up, we evaluated the association between community size and commute time with prognostic parameters of functional class, walk distance and echocardiography.
      Results: Of the 342 patients identified, 72(21%) patients lived in rural areas, while 26(8%), 49(14%) and 195(57%) resided in small, medium and large population centres, respectively. The commute time was <1 h for 160(47%), 1–3 h for 62(18%), and >3 h for 120(35%). There was no association seen for any catheterization parameter by either community size or commute time. At last follow up, there was no association between any prognostic parameter and community size or commute time.
      Conclusions: We found no association between community size or commute time with severity of illness at diagnosis, or markers of prognosis at follow up. This suggests that patients who reside in rural or remote environments are not experiencing deficiencies in care compared to urban patients.


      To read this article in full you will need to make a payment


      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)
        • Galiè Nazzareno
        • Humbert Marc
        • Vachiery Jean-Luc
        • Gibbs Simon
        • Lang Irene
        • Torbicki Adam
        • Simonneau Gérald
        • Peacock Andrew
        • Noordegraaf Anton Vonk
        • Beghetti Maurice
        • Ghofrani Ardeschir
        • Sanchez Miguel Angel Gomez
        • Hansmann Georg
        • Klepetko Walter
        • Lancellotti Patrizio
        • Matucci Marco
        • McDonagh Theresa
        • Pierard Luc A.
        • Trindade Pedro T.
        • Zompatori Maurizio
        • Hoeper Marius
        Eur Respir J. 2015; 46 (The European respiratory journal. 2015 Dec;46(6):1855–6): 903-975
        • Klinger J.R.
        • Elliott C.G.
        • Levine D.J.
        • Bossone E.
        • Duvall L.
        • Fagan K.
        • et al.
        Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report.
        Chest. 2019 Mar; 155: 565-586
        • McLaughlin V.V.
        Looking to the future: a new decade of pulmonary arterial hypertension therapy.
        Eur. Respir. Rev. Off. J. Eur. Resp. Soc. 2011 Dec; 20: 262-269
        • Galiè N.
        • Rubin L.
        • Hoeper M.
        • Jansa P.
        • Al-Hiti H.
        • Meyer G.
        • et al.
        Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
        Lancet. 2008; 371: 2093-2100
        • Galiè N.
        • Barberà J.A.
        • Frost A.E.
        • Ghofrani H.
        • Hoeper M.M.
        • McLaughlin V.V.
        • et al.
        Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.
        New Engl. J. Med. 2015 Aug 27; 373: 834-844
        • Deaño R.C.
        • Glassner-Kolmin C.
        • Rubenfire M.
        • Frost A.
        • Visovatti S.
        • McLaughlin V.V.
        • et al.
        Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the Multicenter RePHerral Study.
        JAMA Intern. Med. 2013 May 27; 173: 887-893
        • Sahay S.
        • Melendres-Groves L.
        • Pawar L.
        • Cajigas H.R.
        Pulmonary hypertension care center network: improving care and outcomes in pulmonary hypertension.
        Chest. 2017 Apr; 151: 749-754
        • Vachiery J.
        • Gaine S.
        Challenges in the diagnosis and treatment of pulmonary arterial hypertension.
        Eur. Respir. Rev. 2012 Sep; 21: 313-320
        • Statistics Canada
        Dictionary, Census of Population, 2016.
        2017 Nov 29
        • Rosenkranz S.
        • Preston I.R.
        Right heart catheterisation: best practice and pitfalls in pulmonary hypertension.
        Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 2015 Dec; 24: 642-652
        • Anderson J.J.
        • Lau E.M.
        • Lavender M.
        • Benza R.
        • Celermajer D.S.
        • Collins N.
        • et al.
        Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand pulmonary hypertension registry cohort.
        Chest. 2020 Jan; 157: 162-172
        • Boucly A.
        • Weatherald J.
        • Savale L.
        • Jaïs X.
        • Cottin V.
        • Prevot G.
        • et al.
        Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.
        Eur. Respir. J. 2017 Aug 03; 50: 1700889
      1. Kylhammar D, Kjellströ B, Hjalmarsson C, Jansson K, Nisell M, Sö Derberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.

        • Galie N.
        • Channick R.N.
        • Frantz R.P.
        • Grunig E.
        • Jing Z.C.
        • Moiseeva O.
        • et al.
        Risk stratification and medical therapy of pulmonary arterial hypertension.
        Eur. Respir. J. 2019; 53: 1-11
        • Primm K.
        • Ferdinand A.O.
        • Callaghan T.
        • Akinlotan M.A.
        • Towne S.D.
        • Bolin J.
        Congestive heart failure-related hospital deaths across the urban-rural continuum in the United States.
        Prev. Med. Rep. 2019 Dec; 16: 101007
        • Sun L.Y.
        • Tu J.V.
        • Sherrard H.
        • Rodger N.
        • Coutinho T.
        • Turek M.
        • et al.
        Sex-specific trends in incidence and mortality for urban and rural ambulatory patients with heart failure in eastern Ontario from 1994 to 2013.
        J. Card. Fail. 2018 Sep; 24: 568-574
        • Lenzi J.
        • Avaldi V.M.
        • Molinazzi D.
        • Descovich C.
        • Urbinati S.
        • Cappelli V.
        • et al.
        Are degree of urbanisation and travel times to healthcare services associated with the processes of care and outcomes of heart failure? A retrospective cohort study based on administrative data.
        PLoS One. 2019; 14e0223845
        • Konishi M.
        • Matsuzawa Y.
        • Ebina T.
        • Kosuge M.
        • Gohbara M.
        • Nishimura K.
        • et al.
        Impact of population density on mortality in patients hospitalized for heart failure – JROAD-DPC registry analysis.
        J. Cardiol. 2020 Apr; 75: 447-453
        • Al-Omary M.S.
        • Davies A.J.
        • Khan A.A.
        • McGee M.
        • Bastian B.
        • Leitch J.
        • et al.
        Heart failure Hospitalisations in the hunter New England area over 10 years. A changing trend.
        Heart Lung Circul. 2016; 26: 627-630
        • Chondur R.
        • Li S.Q.
        • Guthridge S.
        • Lawton P.
        Does relative remoteness affect chronic disease outcomes? Geographic variation in chronic disease mortality in Australia, 2002–2006.
        Aust. N. Z. J. Public Health. 2014 Apr; 38: 117-121
        • Zeng D.
        • You W.
        • Mills B.
        • Alwang J.
        • Royster M.
        • Anson-Dwamena R.
        A closer look at the rural-urban health disparities: insights from four major diseases in the Commonwealth of Virginia.
        Soc. Sci. Med. 2015 Sep; 140: 62-68
        • Loree J.M.
        • Javaheri K.R.
        • Lefresne S.V.
        • Speers C.H.
        • Ruan J.Y.
        • Chang J.T.
        • et al.
        Impact of travel distance and urban-rural status on the multidisciplinary management of rectal cancer.
        J. Rural. Health. 2017; 33: 393-401
        • Khou V.
        • Anderson J.J.
        • Strange G.
        • Corrigan C.
        • Collins N.
        • Celermajer D.S.
        • et al.
        Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry.
        Respirology (Carlton, Vic.). 2020 Aug; 25: 863-871